J Clin Psychiatry 2012;73(3):401 [letter]
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
In the Academic Highlights “Challenges and Solutions in Developing New Medications for Schizophrenia” (J Clin Psychiatry 2010;71:1391–1399), all Ki values in the section “New Antipsychotics and Investigational Agents” should be pKi values. Table 1 should be corrected as follows: the pKi of iloperidone is 0.3 nM for a1 and the pKi of asenapine is 1.3 nM for D2, 0.07 nM for 5-HT2A, 2.7 nM for 5-HT1A, 0.11 nM for 5-HT7, 1.2 nM for both a1 and a2, 1.0 nM for H1, and > 5,000 nM for M1. Additionally, in the “Muscarinic (M1) Effects” section on page 1396, asenapine should be deleted from the list of agents with potent affinity for the M1 receptor.
J CLin Psychiatry 2012; 73(3):401
© 2012 Physicians Postgraduate Press, Inc.